Neurogene
NGNE
66 hedge funds and large institutions have $483M invested in Neurogene in 2024 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 16 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 14
38% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 16
10% more funds holding
Funds holding: 60 → 66 (+6)
7.81% more ownership
Funds ownership: 94.39% → 102.2% (+7.8%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
22% less capital invested
Capital invested by funds: $617M → $483M (-$135M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$19.1M |
| 2 |
RI
RTW Investments
New York
|
+$10.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$9.25M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$8.65M |
| 5 |
State Street
Boston,
Massachusetts
|
+$6.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$15.2M |
| 2 |
ACM
Altium Capital Management
New York
|
-$5.09M |
| 3 |
Morgan Stanley
New York
|
-$4.72M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$3.19M |
| 5 |
Jane Street
New York
|
-$2.79M |
NGNE Hedge Fund Activity: Q2 2024 in Review
66 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q2 2024, worth a combined $483M — down 22% from $617M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new NGNE positions and 16 closed out — a net gain of 6 holders — while 20 added to existing stakes and 14 trimmed.
The largest buyer was BlackRock, adding an estimated $19.1M. The largest seller was Cormorant Asset Management, cutting an estimated $15.2M.
- 66 institutional investors held Neurogene (NGNE) as of Q2 2024, up from 60 in Q1 2024.
- Funds reported $483M of Neurogene stock for Q2 2024, down 22% quarter-over-quarter.
- 22 funds opened new Neurogene positions in Q2 2024 and 16 closed out, a net change of +6 holders.
- The largest Neurogene buyer in Q2 2024 was BlackRock, an estimated $19.1M added.
- The largest Neurogene seller in Q2 2024 was Cormorant Asset Management, an estimated $15.2M sold.
Based on aggregated 13F filings for Q2 2024.